Jack Khouri
@khouri_jack
Hematologic Oncology @ClevelandClinic | Asst Prof @CleClinicLCM of @CWRUSOM
ID:1000352595708383232
https://my.clevelandclinic.org/staff/21595-jack-khouri 26-05-2018 12:26:59
1,1K Tweet
1,0K Takipçi
654 Takip Edilen
CHIP is more prevalent in AL Amyloidosis patients than the general population, but not associated with worse survival outcomes #mmsm #amyloidosis Bianchi Lab Niccolo Bolli Blood Advances ashpublications.org/bloodadvances/…
Patients with no detectable FLC by mass spectrometry have significantly better OS and organ response irrespective of conventional hematologic response #mmsm #amyloidosis Joshua Bomsztyk awechalekar Blood Journal ashpublications.org/blood/article-…
I love this figure from a recent review of high risk MM by Matthew Rees and Shaji Kumar in AmericanJournalofHematology. Risk is a spectrum that involves so much more than cytogenetics and ISS stage! #mmsm
onlinelibrary.wiley.com/doi/full/10.10…
Dara-KRd and Dara-VRd for transplant-eligible NDMM with high cytogenetic risk. Inferior PFS with both quadruplets with >/= 2 HRCA #mmsm #bmtsm Natalie Callander Plasma Cell Pete Luciano J Costa Blood Cancer Journal nature.com/articles/s4140…
#Myeloma Paper of the Day: Study of immune fitness & teclistamab finds responders had higher baseline total T-cell counts, lower Tregs, fewer T-cells expressing co-inhibitory receptors, less soluble BCMA, and T-cell profile with more cytolytic potential: pubmed.ncbi.nlm.nih.gov/38657201/.
Imp manuscript from the Mayo group Saurabh Zanwar showing the outcomes of pts w/ suboptimal response to DaraVCd in NDAL. I have traditionally switched to BCL2 inhibition ASAP if t(11;14) but for the rest such a tricky spot! Hopeful for TCE in this popn
nature.com/articles/s4137…
#Myeloma Paper of the Day: Study of real world impact of bridging therapy prior to CAR T finds response showed no significant association with CRS, ICANS rates, or 3-month post-CAR-T response, and median PFS didn’t significantly differ based on response: pubmed.ncbi.nlm.nih.gov/38609386/.
Huge win for #myeloma patients today! The ODAC committee approved MRD testing as an early endpoint for MM drugs in trials. This accelerates progress towards new treatments! Thank you all who participated Nikhil C. Munshi, MD C. Ola Landgren, M.D. International Myeloma Foundation + #mmsm myeloma.org/news-events/mu…
Thanks Robert Z. Orlowski for highlighting this brief correspondence on artificial intelligence, which is more common than you would think! #AI #mmsm Ludovic Saba Chakra Chaulagain MD FACP Jack Khouri Faiz Anwer MD Cleveland Clinic MD
It is an honor to collaborate with our colleagues Beth Faiman PhD Faiz Anwer MD Jack Khouri on this project from Cleveland Clinic Florida Maroone Cancer at Cleveland Clinic Florida Ludovic Saba
Congratulations to Dr. Matt Kalaycio Cleveland Clinic MD Cleveland Clinic - new chair of National Comprehensive Cancer Network (NCCN) board of directors John Suh Case Comp Cancer Ctr !